Telix Completes Acquisition of ARTMS to Advance Medical Isotope Production
Acquisition Strengthens Telix's Position in the Global Medical Isotope Market
ARTMS' Expertise Enhances Telix's Innovation Leadership
Melbourne, Australia – 11 April 2024 – Telix Pharmaceuticals Limited (ASX: TLX, TLX.N) today announced the completion of the acquisition of ARTMS Inc., a leading radioisotope production technology company based in Vancouver, British Columbia, Canada.
ARTMS specializes in the physics, chemistry, and production of radioisotopes, and has been a key player in the development of novel radioisotope applications in medical imaging and therapy. The acquisition significantly strengthens Telix's position in the global medical isotope market and enhances its capabilities in innovation and leadership.
"The acquisition of ARTMS is a transformative milestone for Telix," said Dr. Christian Behrenbruch, CEO of Telix. "ARTMS' expertise and technology complement our existing capabilities perfectly, and together we will drive the advancement of medical isotope production and accelerate the development of new and innovative diagnostic and therapeutic solutions."
ARTMS' technology platform includes a proprietary ion beam accelerator and a suite of radioisotope production methods, enabling the efficient and cost-effective production of a wide range of radioisotopes. This technology is highly synergistic with Telix's existing radioisotope production facilities and research and development programs.
ARTMS Alternative Radioisotope Technologies for Medical Science was created to enhance human health through innovation and leadership in medical isotope production. Telix's acquisition of ARTMS demonstrates the company's unwavering commitment to investing in the future of medical isotopes and advancing the field of nuclear medicine.
Comments